Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
about
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@en
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@nl
type
label
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@en
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@nl
prefLabel
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@en
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@nl
P2093
P2860
P50
P1433
P1476
Pharmacogenetic meta-analysis ...... utcomes trials for darapladib.
@en
P2093
Allison Barnes
Astrid Yeo
Colin MacPhee
Harvey D White
Jennifer Aponte
Kelley Johansson
Liling Warren
Michelle L O'Donoghue
Richard Davies
Stephanie Chissoe
P2860
P304
P356
10.1371/JOURNAL.PONE.0182115
P407
P577
2017-07-28T00:00:00Z